Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-14 vs 3+7 vs AB-14 in newly diagnosed AML
ChiCTR2500108872Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of azacitidine, venetoclax and tucidinostat in acute myeloid leukemia (AML) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Composite complete remission rate. Started Sep 2025; status: recruiting.
02
Drugs
azacitidinevenetoclaxtucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500108872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108872.